Atypical Hemolytic Uremic Syndrome Ahus Market

DelveInsight's "Atypical Hemolytic Uremic Syndrome (aHUS) - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the atypical hemolytic uremic syndrome (aHUS), historical and forecasted epidemiology as well as the atypical hemolytic uremic syndrome (aHUS) market trends in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 

The Atypical Hemolytic Uremic Syndrome (aHUS) market report provides current treatment practices, emerging drugs, atypical hemolytic uremic syndrome (aHUS) market share of the individual therapies, current and forecasted atypical hemolytic uremic syndrome (aHUS) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current atypical hemolytic uremic syndrome (aHUS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Atypical Hemolytic Uremic Syndrome (aHUS) Understanding and Treatment Algorithm

The DelveInsight’s Atypical Hemolytic Uremic Syndrome (aHUS) market report gives a thorough understanding of the disease. Atypical Hemolytic Uremic Syndrome (aHUS) is defined as a rare cause of thrombotic microangiopathy (TMA), characterized by micro-angiopathic hemolytic anemia, consumptive thrombocytopenia, and multisystem end organ involvement, most commonly affecting the kidney.

 

Most cases of aHUS are genetic, although some may be acquired due to autoantibodies or occur for unknown reasons (idiopathic). aHUS may become chronic, and affected individuals may experience repeated episodes of the disorder. Unlike individuals with typical HUS, who usually recover from the life-threatening initial episode and usually respond well to supportive treatment, individuals with aHUS are much more likely to develop serious chronic complications such as severe high blood pressure (hypertension) and kidney (renal) failure.

 

aHUS is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. These clots can cause serious medical problems if they restrict or block blood flow. It is characterized by three major features related to abnormal clotting: hemolytic anemia, thrombocytopenia, and kidney failure.

 

Hemolytic Uremic Syndrome (HUS) is one of the disorders that belong to the spectrum of thrombotic microangiopathy (TMA). TMAs are a group of life-threatening diseases characterized by endothelial dysfunction and the presence of thrombi in small blood vessels. As the thrombus forms, there is the consumption of platelets and mechanical disruption of erythrocytes, which leads to thrombocytopenia and microangiopathic hemolytic anemia. Vessel occlusion results in tissue ischemia and organ damage, mainly affecting the kidneys, although other organs can be involved.

 

Diagnosing aHUS is complicated by the fact that it is more difficult to establish without a family history of the disorder. The diagnostic criteria associated with aHUS are hemolytic anemia (anemia in the presence of broken red blood cells), low platelet count (thrombocytopenia), and kidney dysfunction.

 

Most of the time, aHUS does not present with initial severe symptoms. The initial onset will most likely appear to be flu-like, with lethargic behavior, pale color, and a loss of appetite. It has been experienced that adult hospitals may often send the patient home with a flu diagnosis, while children’s hospitals may do a blood draw and conduct basic tests, such as Hemoglobin, Hematocrit, white blood cell counts, and platelet counts.

 

After initial blood tests, the hospital may conduct creatinine and BUN tests and may (or may not) reach an initial diagnosis of aHUS. The flu-like symptoms described above will continue to worsen when episodes are active. At this point, kidney function may begin to fall, often quite dramatically. Other organs sometimes experience problems in some cases. Quite often, seizures have been reported, along with other neurological issues. Sometimes gastronomical problems occur as well.

 

aHUS is a diagnosis of exclusion, ruling out (STEC) infection and other secondary causes of TMA , including (TTP). To exclude TTP, a blood test that measures the level of a protein called ADAMTS13 is used. The diagnostic tests for aHUS include blood tests (CBC and eGFR), specific test to differ from TTP, and genetic testing.

 

Treatment

Treatment of aHUS is supportive, with attention to management of acute kidney injury and systemic complications. The use of packed cells is necessary in patients with severe anemia. Platelet transfusions are rarely required, except in counts are <10 000/cu mm, or thrombocytopenia associated with active bleeding or in patients undergoing invasive procedures.

 

Fluid and electrolyte management is important to maintain intravascular volume status and combat the consequences of aHUS, acute kidney injury, and multisystem organ failure. Electrolyte disturbances should be promptly corrected and nephrotoxic medications avoided. Hypertension should be managed with appropriate agents. Renal replacement therapy is required in patients with uremia, fluid overload, or electrolyte abnormalities. Plasma exchange and eculizumab or rivalizumab, a complement inhibitor, offer specific forms of therapy.

 

For years, plasma therapy was the standard treatment for individuals with aHUS. Both infusions of fresh frozen plasma (plasma infusion), as well as plasma exchange (plasmapheresis), were utilized. Fresh frozen plasma is a blood derivative that is obtained from donors. Plasma exchange removes potentially harmful substances (e.g., toxins, metabolic substances, and plasma parts) from the blood. Blood is removed from the affected individual, and blood cells are separated from the plasma. The plasma is then replaced with other human plasma, and the blood is transfused into the affected individuals. Plasma exchange can also remove mutant factors and autoantibodies.

Atypical Hemolytic Uremic Syndrome (aHUS) Epidemiology

The Atypical Hemolytic Uremic Syndrome epidemiology division provides insights about historical and current Atypical Hemolytic Uremic Syndrome patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

In the year 2021, the total prevalent cases of Atypical Hemolytic Uremic Syndrome were 7,042 in the 7MM which are expected to grow during the study period, i.e., 2019–2032.

 

The disease epidemiology covered in the report provides historical as well as forecasted Atypical Hemolytic Uremic Syndrome epidemiology [segmented as Total Prevalent Cases of Atypical hemolytic uremic syndrome, Total Diagnosed Cases of Atypical hemolytic uremic syndrome, Total Age group-specific Cases of Atypical hemolytic uremic syndrome, and Total Treated Cases of Atypical hemolytic uremic syndrome] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Atypical Hemolytic Uremic Syndrome (aHUS) Epidemiology

The epidemiology segment also provides the Atypical Hemolytic Uremic Syndrome epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Atypical Hemolytic Uremic Syndrome (aHUS) Drug Chapters

The drug chapter segment of the Atypical Hemolytic Uremic Syndrome report encloses the detailed analysis of Atypical Hemolytic Uremic Syndrome marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Atypical Hemolytic Uremic Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Atypical Hemolytic Uremic Syndrome treatment.

Atypical Hemolytic Uremic Syndrome (aHUS) Market Outlook

The Atypical Hemolytic Uremic Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Atypical Hemolytic Uremic Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, barriers, and demand for better technology.This segment gives a thorough detail of Atypical Hemolytic Uremic Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Atypical Hemolytic Uremic Syndrome market in 7MM is expected to witness a major change in the study period 2019–2032.

 

Key Findings

The Atypical Hemolytic Uremic Syndrome market size in the 7MM is expected to change during the study period 2019–2032. The therapeutic market of Atypical Hemolytic Uremic Syndrome in the seven major markets is expected to increase during the study period (2019–2032). In 2021, the total market size of Atypical Hemolytic Uremic Syndrome was USD 1,248.8 million which is expected to rise during the study period (2019–2032).

 

The United States Market Outlook

The total market size of Atypical Hemolytic Uremic Syndrome in the United States accounted for USD 783.5 million in 2021 which is expected to rise during the study period (2019–2032).

 

EU-5 Countries: Market Outlook

In EU-5, the total market size of Atypical Hemolytic Uremic Syndrome was USD 419 million in 2021, which is expected to rise during the study period (2019–2032).

 

Japan Market Outlook

In Japan, the total market size of Atypical Hemolytic Uremic Syndrome was USD 46.3 million in 2021, which is expected to rise during the study period (2019–2032).

Atypical Hemolytic Uremic Syndrome (aHUS) Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Atypical Hemolytic Uremic Syndrome market or expected to get launched in the market during the study period 2019-2032. The analysis covers Atypical Hemolytic Uremic Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Atypical Hemolytic Uremic Syndrome (aHUS) Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Atypical Hemolytic Uremic Syndrome key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers detailed information on collaborations, acquisition, and merger, licensing patent details, and other information for Atypical Hemolytic Uremic Syndrome emerging therapies.

Reimbursement Scenario in Atypical Hemolytic Uremic Syndrome (aHUS)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Atypical Hemolytic Uremic Syndrome domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Atypical Hemolytic Uremic Syndrome market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitively and Market Intelligence analysis of the Atypical Hemolytic Uremic Syndrome Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTEL analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Atypical Hemolytic Uremic Syndrome, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
  • Comprehensive insight has been provided into the Atypical Hemolytic Uremic Syndrome epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Atypical Hemolytic Uremic Syndrome are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Atypical Hemolytic Uremic Syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Atypical Hemolytic Uremic Syndrome market.

Report Highlights

  • In the coming years, the Atypical Hemolytic Uremic Syndrome market is set to change due to the upcoming therapies with novel route of administrations which are under investigation and ongoing research in the aHUS; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Atypical Hemolytic Uremic Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Atypical Hemolytic Uremic Syndrome. The launch of emerging therapies will significantly impact the Atypical Hemolytic Uremic Syndrome market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Atypical Hemolytic Uremic Syndrome.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Atypical Hemolytic Uremic Syndrome (aHUS) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Atypical Hemolytic Uremic Syndrome (aHUS) Pipeline Analysis
  • Atypical Hemolytic Uremic Syndrome (aHUS)  Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Atypical Hemolytic Uremic Syndrome (aHUS) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Atypical Hemolytic Uremic Syndrome Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Atypical Hemolytic Uremic Syndrome (aHUS) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Atypical Hemolytic Uremic Syndrome drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Atypical Hemolytic Uremic Syndrome total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings of the market across 7MM and which country will have the largest Atypical Hemolytic Uremic Syndrome market size during the forecast period (2019-2032)?
  • At what CAGR, the Atypical Hemolytic Uremic Syndrome market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the Atypical Hemolytic Uremic Syndrome market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Atypical Hemolytic Uremic Syndrome market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of Atypical Hemolytic Uremic Syndrome?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU-5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Atypical Hemolytic Uremic Syndrome patient pool in seven major markets covering the United States, EU-5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Atypical Hemolytic Uremic Syndrome in seven major markets covering the United States, EU-5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM concerning the patient population about Atypical Hemolytic Uremic Syndrome?
  • Out of all 7MM countries, which country would have the highest prevalent population of Atypical Hemolytic Uremic Syndrome during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

What are the current options for the Atypical Hemolytic Uremic Syndrome treatment in addition to the approved therapies?

  • What are the current treatment guidelines for the treatment of Atypical Hemolytic Uremic Syndrome in the USA, Europe, and Japan?
  • What are the Atypical Hemolytic Uremic Syndrome marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Atypical Hemolytic Uremic Syndrome?
  • How many therapies are in-development by each company for Atypical Hemolytic Uremic Syndrome treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Atypical Hemolytic Uremic Syndrome treatment?
  • What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Atypical Hemolytic Uremic Syndrome therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Atypical Hemolytic Uremic Syndrome and their status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for Atypical Hemolytic Uremic Syndrome?
  • What are the global historical and forecasted markets of Atypical Hemolytic Uremic Syndrome?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Atypical Hemolytic Uremic Syndrome market
  • To understand the future market competition in the Atypical Hemolytic Uremic Syndrome market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Atypical Hemolytic Uremic Syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Atypical Hemolytic Uremic Syndrome market
  • To understand the future market competition in the Atypical Hemolytic Uremic Syndrome market

1. Key Insights

2. Report Introduction

3. Atypical Hemolytic Uremic Syndrome (aHUS) Market Overview at a Glance

3.1. Market Share (%) Distribution of aHUS in 2019

3.2. Market Share (%) Distribution of aHUS in 2032

4. Executive Summary of Atypical Hemolytic Uremic Syndrome (aHUS)

4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Types of Hemolytic Uremic Syndrome

6.3. Risk Factors and Causes of Atypical Hemolytic Uremic Syndrome

6.4. Signs and Symptoms of Atypical Hemolytic Uremic Syndrome

6.5. Pathophysiology of Atypical Hemolytic Uremic Syndrome

6.6. Complement Protein Mutations

6.7. Clinical Manifestations of Atypical Hemolytic Uremic Syndrome

7. Diagnosis and Differential Diagnosis of Atypical Hemolytic Uremic Syndrome

7.1. Diagnostic Algorithm of Atypical Hemolytic Uremic Syndrome

7.2. Blood Tests

7.3. Specific Testing

7.4. Genetic Testing

7.5. Differential Diagnosis

8. Diagnostic Guidelines

8.1. The Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society

8.2. Clinical Practice Guidelines for the management of atypical Hemolytic Uremic Syndrome in the United Kingdom

9. Current Treatment Practices of Atypical Hemolytic Uremic Syndrome

9.1. Treatment Algorithm of Atypical hemolytic uremic syndrome

9.1.1. Plasma Exchange

9.1.2. Eculizumab

9.1.3. Ravulizumab

9.1.4. Kidney Transplant

9.1.5. Liver transplantation

10. Treatment Guidelines

10.1. The European Rare Kidney Disease Reference Network guidelines for the management of atypical hemolytic uremic syndrome in children

10.2. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in the United Kingdom

10.3. National Institute for Health and Research

11. Conclusion

12. Epidemiology and Patient Population

12.1. Key Findings

12.2. Assumptions and Rationale: 7MM

12.3. Epidemiology Scenario

12.3.1. Total Prevalent Cases of aHUS in the 7MM

13. Aypical Hemolytic Uremic Syndrome: Country-wise Epidemiology

13.1. The United States

13.1.1. Total Prevalent Cases of aHUS in the United States

13.1.2. Total Diagnosed Cases of aHUS in the United States

13.1.3. Total Age group-specific Cases of aHUS in the United States

13.1.4. Total Treated Cases of aHUS in the US

13.2. EU5 Countries

13.2.1. Germany

13.2.2. France

13.2.3. Italy

13.3. Spain

13.4. United Kingdom

13.5. Japan

13.5.1. Total Prevalent Cases of aHUS in  Japan

13.5.2. Total Diagnosed Cases of aHUS in Japan

13.5.3. Total Age group-specific Cases of aHUS in Japan

13.5.4. Total Treated Cases of aHUS in Japan

14. Patient Journey

15. Key Endpoints in Atypical Hemolytic Uremic Syndrome (aHUS) Clinical Trials

16. Marketed Therapies

16.1. Soliris (Eculizumab): Alexion Pharmaceuticals

16.1.1. Drug Description

16.1.2. Regulatory Milestones

16.1.3. Other Developmental Activities

16.1.4. Pivotal Clinical Trial

16.2. Ultomiris (Ravulizumab): Alexion Pharmaceuticals

16.2.1. Drug Description

16.2.2. Regulatory Milestones

16.2.3. Other Developmental Activities

16.2.4. Pivotal Clinical Trial

16.2.5. Ongoing Current Pipeline Activity

17. Emerging Therapies

17.1. Narsoplimab (OMS721): Omeros Corporation

17.1.1. Product Description

17.1.2. Other Developmental Activities

17.1.3. Clinical Developmental Activities

17.1.4. Safety and Efficacy

17.1.5. Analyst’s Views

17.2. Iptacopan (LNP 023): Novartis Pharmaceuticals

17.2.1. Product Description

17.2.2. Clinical Developmental Activities

17.2.3. Analyst’s Views

17.3. Crovalimab (RG6107; SKY59): Hoffmann-La Roche/Chugai Pharmaceutical

17.3.1. Product Description

17.3.2. Clinical Developmental Activities

17.3.3. Analyst’s Views

18. Conjoint Analysis

19. Atypical Hemolytic Uremic Syndrome: 7 Major Market Analysis

19.1. Key Findings

19.2. Market Outlook

19.3. Market Size of Atypical Hemolytic Uremic Syndrome in the 7MM

19.4. Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in the 7MM

19.5. Market Size in the United States

19.5.1. Total Market Size of Atypical Hemolytic Uremic Syndrome

19.5.2. Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in the United States

19.6. Market Size in the EU-5

19.6.1. Germany Market size

19.6.2. France Market size

19.6.3. Italy Market size

19.6.4. Spain Market size

19.6.5. United Kingdom Market size

19.6.6. Japan Market Size

20. Market Access and Reimbursement

20.1. Key HTA decisions for aHUS

20.2. Reimbursement

20.3. Patient Access Programs

21. KOL Views

22. Market Drivers

23. Market Barriers

24. SWOT Analysis

25. Unmet needs

26. Appendix

26.1. Bibliography

26.2. Report Methodology

27. DelveInsight Capabilities

28. Disclaimer

29. About DelveInsight

List of Table

Table 1: Summary of Atypical Hemolytic Uremic Syndrome (aHUS) Disease, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Frequency of Genetic Variants in Complement Regulatory Factors, According to Geographic Locations

Table 3: Recommended Evaluations Following Initial Diagnosis in Individuals with Genetic Atypical Hemolytic Uremic Syndrome

Table 4: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in the 7MM (2019–2032)

Table 5: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in the US (2019–2032)

Table 6: Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome in the US (2019–2032)

Table 7: Total Age group-specific Cases of Atypical Hemolytic Uremic Syndrome in the US (2019–2032)

Table 8: Total Treated Cases of Atypical Hemolytic Uremic Syndrome in the US (2019–2032)

Table 9: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in Germany (2019–2032)

Table 10: Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome in Germany (2019–2032)

Table 11: Total Age group-specific Cases of Atypical Hemolytic Uremic Syndrome in Germany (2019–2032)

Table 12: Total Treated Cases of Atypical Hemolytic Uremic Syndrome in Germany (2019–2032)

Table 13: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in France (2019–2032)

Table 14: Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome in France (2019–2032)

Table 15: Total Age group-specific Cases of Atypical Hemolytic Uremic Syndrome in France (2019–2032)

Table 16: Total Treated Cases of Atypical Hemolytic Uremic Syndrome in France (2019–2032)

Table 17: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in Italy (2019–2032)

Table 18: Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome in Italy (2019–2032)

Table 19: Total Age group-specific Cases of Atypical Hemolytic Uremic Syndrome in Italy (2019–2032)

Table 20: Total Treated Cases of Atypical Hemolytic Uremic Syndrome in Italy (2019–2032)

Table 21: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in Spain (2019–2032)

Table 22: Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome in Spain (2019–2032)

Table 23: Total Age group-specific Cases of Atypical Hemolytic Uremic Syndrome in Spain (2019–2032)

Table 24: Total Treated Cases of Atypical Hemolytic Uremic Syndrome in Spain (2019–2032)

Table 25: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in the United Kingdom (2019–2032)

Table 26: Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome in the United Kingdom (2019–2032)

Table 27: Total Age group-specific Cases of Atypical Hemolytic Uremic Syndrome in the United Kingdom (2019–2032)

Table 28: Total Treated Cases of Atypical Hemolytic Uremic Syndrome in the United Kingdom (2019–2032)

Table 29: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in Japan (2019–2032)

Table 30: Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome in Japan (2019–2032)

Table 31: Total Age group-specific Cases of Atypical Hemolytic Uremic Syndrome in Japan (2019–2032)

Table 32: Total Treated Cases of Atypical Hemolytic Uremic Syndrome in Japan (2019–2032)

Table 33: Dosing Recommendations in aHUS Patients Less Than 18 Years of Age

Table 34: Ultomiris Weight-based Dosing Regimen aHUS

Table 35: Ultomiris (Ravulizumab), Clinical Trial Description, 2022

Table 36: Narsoplimab (OMS721), Clinical Trial Description, 2022

Table 37: Iptacopan (LNP023), Clinical Trial Description, 2022

Table 38: Crovalimab (RG6107; SKY59), Clinical Trial Description, 2022

Table 39: 7MM Market Size of Atypical Hemolytic Uremic Syndrome in USD Million (2019–2032)

Table 40: 7MM Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in USD Million (2019–2032)

Table 41: Market Size of Atypical Hemolytic Uremic Syndrome in the United States, in USD Million (2019–2032)

Table 42: Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in the United States, in USD Million (2019–2032)

Table 43: Market Size of Atypical Hemolytic Uremic Syndrome in Germany, in USD Million (2019–2032)

Table 44: Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in Germany, in USD Million (2019–2032)

Table 45: Market Size of Atypical Hemolytic Uremic Syndrome in France, in USD Million (2019–2032)

Table 46: Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in France, in USD Million (2019–2032)

Table 47: Market Size of Atypical Hemolytic Uremic Syndrome in France, in USD Million (2019–2032)

Table 48: Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in Italy, in USD Million (2019–2032)

Table 49: Market Size of Atypical Hemolytic Uremic Syndrome in Spain, in USD Million (2019–2032)

Table 50: Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in Spain, in USD Million (2019–2032)

Table 51: Market Size of Atypical Hemolytic Uremic Syndrome in the United Kingdom, in USD Million (2019–2032)

Table 52: Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in the United Kingdom, in USD Million (2019–2032)

Table 53: Market Size of Atypical Hemolytic Uremic Syndrome in Japan, in USD Million (2019–2032)

Table 54: Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in Japan, in USD Million (2019–2032)

Table 55: Key HTA Decisions

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Relationship of the Thrombotic Microangiopathy Lesions

Figure 3: Understanding of Atypical Hemolytic Uremic Syndrome

Figure 4: Risk Factors and Causes of Atypical Hemolytic Uremic Syndrome

Figure 5: Triggering Factors for Atypical Hemolytic Uremic Syndrome

Figure 6: Pathophysiology of Atypical Hemolytic Uremic Syndrome

Figure 7: Clinical Manifestations of Atypical Hemolytic Uremic Syndrome

Figure 8: Extra-renal Manifestations of Atypical Hemolytic Uremic Syndrome

Figure 9: Diagnostic Algorithm of Atypical Hemolytic Uremic Syndrome

Figure 10: Differential Diagnosis of Hemolytic Uremic Syndrome

Figure 11: Differential Diagnosis

Figure 12: Algorithm for Differential Diagnosis of aHUS

Figure 13: Treatment Algorithm of atypical HUS

Figure 14: Blockade of Terminal Complement Activation by Eculizumab

Figure 15: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in the 7MM (2019–2032)

Figure 16: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in the US (2019–2032)

Figure 17: Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome in the US (2019–2032)

Figure 18: Total Age group-specific Cases of Atypical Hemolytic Uremic Syndrome in the US (2019–2032)

Figure 19: Total Treated Cases of Atypical Hemolytic Uremic Syndrome in the US (2019–2032)

Figure 20: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in Germany (2019–2032)

Figure 21: Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome in Germany (2019–2032)

Figure 22: Total Age group-specific Cases of Atypical Hemolytic Uremic Syndrome in Germany (2019–2032)

Figure 23: Total Treated Cases of Atypical Hemolytic Uremic Syndrome in Germany (2019–2032)

Figure 24: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in France (2019–2032)

Figure 25: Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome in France (2019–2032)

Figure 26: Total Age group-specific Cases of Atypical Hemolytic Uremic Syndrome in France (2019–2032)

Figure 27: Total Treated Cases of Atypical Hemolytic Uremic Syndrome in the France (2019–2032)

Figure 28: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in Italy (2019–2032)

Figure 29: Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome in Italy (2019–2032)

Figure 30: Total Age group-specific Cases of Atypical Hemolytic Uremic Syndrome in Italy (2019–2032)

Figure 31: Total Treated Cases of Atypical Hemolytic Uremic Syndrome in Italy (2019–2032)

Figure 32: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in Spain (2019–2032)

Figure 33: Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome in Spain (2019–2032)

Figure 34: Total Age group-specific Cases of Atypical Hemolytic Uremic Syndrome in Spain (2019–2032)

Figure 35: Total Treated Cases of Atypical Hemolytic Uremic Syndrome in Spain (2019–2032)

Figure 36: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in the United Kingdom (2019–2032)

Figure 37: Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome in the United Kingdom (2019–2032)

Figure 38: Total Age group-specific Cases of Atypical Hemolytic Uremic Syndrome in the United Kingdom (2019–2032)

Figure 39: Total Treated Cases of Atypical Hemolytic Uremic Syndrome in the United Kingdom (2019–2032)

Figure 40: Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome in Japan (2019–2032)

Figure 41: Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome in Japan (2019–2032)

Figure 42: Total Age group-specific Cases of Atypical Hemolytic Uremic Syndrome in Japan (2019–2032)

Figure 43: Total Treated Cases of Atypical Hemolytic Uremic Syndrome in Japan (2019–2032)

Figure 44: Market Size of Atypical Hemolytic Uremic Syndrome in the 7MM, USD Million (2019–2032)

Figure 45: 7MM Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in USD Million (2019–2032)

Figure 46: Market Size of Atypical Hemolytic Uremic Syndrome in the United States, USD Million (2019–2032)

Figure 47: Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in the United States, in USD Million (2019–2032)

Figure 48: Market Size of Atypical Hemolytic Uremic Syndrome in Germany, USD Million (2019–2032)

Figure 49: Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in Germany, in USD Million (2019–2032)

Figure 50: Market Size of Atypical Hemolytic Uremic Syndrome in France, in USD Million (2019–2032)

Figure 51: Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in France, in USD Million (2019–2032)

Figure 52: Market Size of Atypical Hemolytic Uremic Syndrome in Italy, in USD Million (2019–2032)

Figure 53: Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in Italy, in USD Million (2019–2032)

Figure 54: Market Size of Atypical Hemolytic Uremic Syndrome in Spain, in USD Million (2019–2032)

Figure 55: Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in Spain, in USD Million (2019–2032)

Figure 56: Market Size of Atypical Hemolytic Uremic Syndrome in the United Kingdom, in USD Million (2019–2032)

Figure 57: Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in the United Kingdom, in USD Million (2019–2032)

Figure 58: Market Size of Atypical Hemolytic Uremic Syndrome in Japan, in USD Million (2019–2032)

Figure 59: Market Size of Atypical Hemolytic Uremic Syndrome by Therapies in Japan, in USD Million (2019–2032)

Figure 60: Market Drivers

Figure 61: Market Barriers

Figure 62: Unmet Needs

Alexion Pharmaceuticals
Omeros Corporation
Novartis Pharmaceuticals
Hoffmann-La Roche
Chugai Pharmaceutical

 

 

Forward to Friend

Need A Quote